• By ICR Secretariat
  • Posted Wednesday, April 15, 2020

AstraZeneca and Merck drug wins approval for rare cancer after failing elsewhere


The Food and Drug Administration approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths.

The drug, which will be sold as Koselugo, previously failed to improve survival in patients with lung cancer and melanoma that had spread to the eye. With this approval in NF1, announced Friday, AstraZeneca has won a rare pediatric disease voucher, which it can use to secure priority review for an experimental drug or sell to another company.